Research Article

Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers

Volume: 9 Number: 4 December 28, 2018
EN TR

Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers

Abstract

Aim: One of the most frequent and reliable methods for determining phototoxicity is to monitor the minimal erythema dose(MED) related to UVA after using the drug.

In our study, it was aimed to determine whether dihydropyridine-derived calcium channel blockers cause phototoxicity.

Material and Methods: Eight open areas of 1 cm2 were left on the backs of the patients. Eight different doses of UVA were applied to these 8 areas starting at 2 j / cm2 and increasing to 16 j / cm2; After 24 hours, the first area which had significant erythema was checked. This value is defined as minimal erythematous dose (MED). MED values of patients were measured before treatment and on the 7th day of treatment.

Results:Thirty-nine hypertensive patients, 20 female and 19 male, were included in the study.

Conclusion: Dihydropyridine-derived calcium channel blockers did not cause a change in MED for UVA and therefore did not cause phototoxicity.

Keywords

References

  1. 1. Moseley H. Elementary photobiology and photophysics. J. Ferguson, J.S.Dover(Eds). Photodermatology (pp.:9-13). London: Manson Publishing, 2006.
  2. 2. Kochever IE, Taylor CR, Krutman J. Fundamentals of cutaneous photobiology and photoimmunulogy. In:K.Wolff, L.A.Goldsmith, S.I.Katz, B.A.Gilchrest, A.S.Paller, D.J.Leffel (eds). Fitzpatrick’s Dermatology in General Medicine (pp.:797-809). 7th ed. New York: McGraw-Hill Book Company, 2008.
  3. 3. Scheinfeld NS, Chernoff K, DerekHo MK, LiuYC.Drug-induced photoallergic and phototoxic reactions - an update. Expert Opin Drug Saf 2014:321-340.
  4. 4. Endres L, Breit R. UV radiation, irradiation, dosimetry. In: Krutmann J, Höningsmann H, Elmets CA, Bergstresser PR (eds). Dermatological phototherapy and photodiagnostic methods (pp.:3-53). Berlin: Springer Verlag, 2000.
  5. 5. Moseley H. Phototest equipment. In: J Ferguson, J.S.Dover (Eds). Photodermatology (pp.:14-20). London: Manson Publishing 2010.
  6. 6. Becker L, Eberlein-Konig B, Przybilla B. Phototoxicity of Non-steroidal Antiinflammatory Drugs: In Vitro Studies with Visible Light. Acta Derm Venereol 1996; 76: 337-40.
  7. 7. Dawe RS, Ibbotson SH. Drug-induced photosensitivity. Dermatol Clin 2014: 363-68.
  8. 8. Ferguson J, Leeming MRG. Lack of photosensitising potential of tenidap, a novel anti-rheumatic agent. Br J Clin Pharmac 1995; 39: 63-66.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Serkan Demirkan *
KIRIKKALE ÜNİVERSİTESİ
0000-0002-3960-3891
Türkiye

Ekin Şavk
Türkiye

Göksun Karaman This is me
Türkiye

Meltem Uslu This is me
Türkiye

Publication Date

December 28, 2018

Submission Date

December 22, 2017

Acceptance Date

May 28, 2018

Published in Issue

Year 2018 Volume: 9 Number: 4

APA
Demirkan, S., Şavk, E., Şendur, N., Karaman, G., & Uslu, M. (2018). Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers. Turkish Journal of Clinics and Laboratory, 9(4), 277-280. https://doi.org/10.18663/tjcl.370070
AMA
1.Demirkan S, Şavk E, Şendur N, Karaman G, Uslu M. Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers. TJCL. 2018;9(4):277-280. doi:10.18663/tjcl.370070
Chicago
Demirkan, Serkan, Ekin Şavk, Neslihan Şendur, Göksun Karaman, and Meltem Uslu. 2018. “Evaluation of Minimal Erythemadose in Patients Who Use Dihydropyridinic Calcium Channel Blockers”. Turkish Journal of Clinics and Laboratory 9 (4): 277-80. https://doi.org/10.18663/tjcl.370070.
EndNote
Demirkan S, Şavk E, Şendur N, Karaman G, Uslu M (December 1, 2018) Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers. Turkish Journal of Clinics and Laboratory 9 4 277–280.
IEEE
[1]S. Demirkan, E. Şavk, N. Şendur, G. Karaman, and M. Uslu, “Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers”, TJCL, vol. 9, no. 4, pp. 277–280, Dec. 2018, doi: 10.18663/tjcl.370070.
ISNAD
Demirkan, Serkan - Şavk, Ekin - Şendur, Neslihan - Karaman, Göksun - Uslu, Meltem. “Evaluation of Minimal Erythemadose in Patients Who Use Dihydropyridinic Calcium Channel Blockers”. Turkish Journal of Clinics and Laboratory 9/4 (December 1, 2018): 277-280. https://doi.org/10.18663/tjcl.370070.
JAMA
1.Demirkan S, Şavk E, Şendur N, Karaman G, Uslu M. Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers. TJCL. 2018;9:277–280.
MLA
Demirkan, Serkan, et al. “Evaluation of Minimal Erythemadose in Patients Who Use Dihydropyridinic Calcium Channel Blockers”. Turkish Journal of Clinics and Laboratory, vol. 9, no. 4, Dec. 2018, pp. 277-80, doi:10.18663/tjcl.370070.
Vancouver
1.Serkan Demirkan, Ekin Şavk, Neslihan Şendur, Göksun Karaman, Meltem Uslu. Evaluation of minimal erythemadose in patients who use dihydropyridinic calcium channel blockers. TJCL. 2018 Dec. 1;9(4):277-80. doi:10.18663/tjcl.370070

e-ISSN: 2149-8296

Publication Model: Continuous Publication

Peer Review Model: Double-Blind Peer Review

Publication Language: Turkish and English

Access Model: Open Access

DOI Prefix: (Crossref DOI numaranız)

Publisher: DNT Ortadoğu Publishing Inc.

Journal Abbreviation: Turk J Clin Lab

Indexed in J-Gate

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.